Rapport Therapeutics (RAPP) Cash from Financing Activities (2023 - 2026)
Rapport Therapeutics' (RAPP) quarterly Cash from Financing Activities came in at $531000.0 in Q1 2026, up 10520.0% year-on-year from N/an in Q1 2025, and up 70.74% on a QoQ basis from $311000.0 in Q4 2025.
Rapport Therapeutics (RAPP) Cash from Financing Activities (2023 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has 4 years of Cash from Financing Activities data on file, last reported at $531000.0 in Q1 2026.
- On a quarterly basis, Cash from Financing Activities rose 10520.0% year-over-year to $531000.0 in Q1 2026; TTM through Mar 2026 was $271.3 million, a 71.75% increase from a year earlier, with the FY2025 full-year figure at $270.8 million, up 22.18% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $531000.0, up from $311000.0 in the prior quarter.
- Over the last five years, Cash from Financing Activities for RAPP reached as high as $270.5 million in Q3 2025 and fell as low as -$1.4 million in Q3 2024.
- Historically, Cash from Financing Activities has averaged $52.6 million across 4 years, with a median of $311000.0 in 2025.
- Across the five-year window, Cash from Financing Activities slumped 101.63% in 2024 and soared 19506.96% in 2025, its largest moves.
- Year by year, Cash from Financing Activities stood at -$140000.0 in 2023, then soared by 105.0% to $7000.0 in 2024, then jumped by 4342.86% to $311000.0 in 2025, then surged by 70.74% to $531000.0 in 2026.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were $531000.0 in Q1 2026, $311000.0 in Q4 2025, and $270.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Rapport Therapeutics | 1.95 Bn | 1.95 Bn | - | 531,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 531,000.00 |
| Mar 31, 2026 | 531,000.00 |
| Dec 31, 2025 | 311,000.00 |
| Dec 31, 2025 | 311,000.00 |
| Sep 30, 2025 | 270.53 Mn |
| Sep 30, 2025 | 270.53 Mn |
| Jun 30, 2025 | -63,000.00 |
| Jun 30, 2025 | -63,000.00 |
| Mar 31, 2025 | 5,000.00 |
| Mar 31, 2025 | 5,000.00 |
| Dec 31, 2024 | 7,000.00 |
| Dec 31, 2024 | 7,000.00 |
| Sep 30, 2024 | -1.39 Mn |
| Sep 30, 2024 | -1.39 Mn |
| Jun 30, 2024 | 159.35 Mn |
| Jun 30, 2024 | 159.35 Mn |
| Mar 31, 2024 | 63.66 Mn |
| Mar 31, 2024 | 63.66 Mn |
| Dec 31, 2023 | -140,000.00 |
| Dec 31, 2023 | -140,000.00 |